Comprehensive Endocrine-Metabolic Evaluation of Patients with Alström Syndrome Compared to BMI-Matched Controls

Comprehensive Endocrine-Metabolic Evaluation of Patients with Alström Syndrome Compared to... Abstract Background Alström syndrome (AS), a monogenic form of obesity, is caused by recessive mutations in the centrosome- and basal body-associated gene, ALMS1. AS is characterized by retinal dystrophy, sensory hearing loss, cardiomyopathy, childhood obesity, and metabolic derangements. Objective We sought to characterize the endocrine and metabolic features of AS while accounting for obesity as a confounder by comparing patients with AS to BMI-matched controls. Methods We evaluated 38 patients with AS (age 2-38y) who were matched with 76 controls (age 2-48y) by age, sex, race, and BMI. Fasting biochemistries, mixed meal test (MMT), indirect calorimetry, DEXA, and MRI/MRS were performed. Results Frequent abnormalities in AS included 76% obesity, 37% type 2 diabetes (T2DM), 29% hypothyroidism (1/3-central, 2/3-primary), 3% central adrenal insufficiency, 57% adult hypogonadism (1/3-central, 2/3-primary), and 25% female hyperandrogenism. AS and controls had similar BMI-Z, body fat, waist circumference, abdominal visceral fat, muscle fat, resting energy expenditure (adjusted for lean mass), free fatty acids, glucagon, prolactin, ACTH, and cortisol. Compared to controls, AS were shorter and had lower IGF1 concentrations (p’s≤0.001). AS had significantly greater fasting and MMT insulin resistance indices, higher MMT glucose, insulin, and C-peptide values, higher hemoglobin A1c, and higher prevalence of T2DM (p’s<0.001). AS had significantly higher triglycerides, lower HDL-cholesterol, and a 10-fold greater prevalence of metabolic syndrome (p’s<0.001). AS demonstrated significantly greater liver triglyceride accumulation and higher transaminases (p’s<0.001). Conclusion Severe insulin resistance and T2DM are the hallmarks of AS. However, patients with AS may present with multiple other endocrinopathies affecting growth and development. Copyright © 2018 Endocrine Society http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Journal of Clinical Endocrinology and Metabolism Oxford University Press

Comprehensive Endocrine-Metabolic Evaluation of Patients with Alström Syndrome Compared to BMI-Matched Controls

Loading next page...
 
/lp/ou_press/comprehensive-endocrine-metabolic-evaluation-of-patients-with-alstr-m-xphaB7oFjQ
Publisher
Endocrine Society
Copyright
Copyright © 2018 Endocrine Society
ISSN
0021-972X
eISSN
1945-7197
D.O.I.
10.1210/jc.2018-00496
Publisher site
See Article on Publisher Site

Abstract

Abstract Background Alström syndrome (AS), a monogenic form of obesity, is caused by recessive mutations in the centrosome- and basal body-associated gene, ALMS1. AS is characterized by retinal dystrophy, sensory hearing loss, cardiomyopathy, childhood obesity, and metabolic derangements. Objective We sought to characterize the endocrine and metabolic features of AS while accounting for obesity as a confounder by comparing patients with AS to BMI-matched controls. Methods We evaluated 38 patients with AS (age 2-38y) who were matched with 76 controls (age 2-48y) by age, sex, race, and BMI. Fasting biochemistries, mixed meal test (MMT), indirect calorimetry, DEXA, and MRI/MRS were performed. Results Frequent abnormalities in AS included 76% obesity, 37% type 2 diabetes (T2DM), 29% hypothyroidism (1/3-central, 2/3-primary), 3% central adrenal insufficiency, 57% adult hypogonadism (1/3-central, 2/3-primary), and 25% female hyperandrogenism. AS and controls had similar BMI-Z, body fat, waist circumference, abdominal visceral fat, muscle fat, resting energy expenditure (adjusted for lean mass), free fatty acids, glucagon, prolactin, ACTH, and cortisol. Compared to controls, AS were shorter and had lower IGF1 concentrations (p’s≤0.001). AS had significantly greater fasting and MMT insulin resistance indices, higher MMT glucose, insulin, and C-peptide values, higher hemoglobin A1c, and higher prevalence of T2DM (p’s<0.001). AS had significantly higher triglycerides, lower HDL-cholesterol, and a 10-fold greater prevalence of metabolic syndrome (p’s<0.001). AS demonstrated significantly greater liver triglyceride accumulation and higher transaminases (p’s<0.001). Conclusion Severe insulin resistance and T2DM are the hallmarks of AS. However, patients with AS may present with multiple other endocrinopathies affecting growth and development. Copyright © 2018 Endocrine Society

Journal

Journal of Clinical Endocrinology and MetabolismOxford University Press

Published: Apr 27, 2018

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off